Cargando…

The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab

INTRODUCTION: We studied the distribution and in vitro pathogenicity of anti-DSG3 IgG subclasses during the course of pemphigus vulgaris (PV). METHODS: We longitudinally studied the distribution of anti-DSG3 IgG subclasses (before versus after treatment) in sera from PV patients, using an addressabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Golinski, Marie-Laure, Lemieux, Alexandre, Maho-Vaillant, Maud, Barray, Marion, Drouot, Laurent, Schapman, Damien, Petit, Marie, Hertl, Michael, Boyer, Olivier, Calbo, Sébastien, Joly, Pascal, Hébert, Vivien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965561/ https://www.ncbi.nlm.nih.gov/pubmed/35371083 http://dx.doi.org/10.3389/fimmu.2022.849790

Ejemplares similares

Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment
por: Petit, Marie, et al.
Publicado: (2021)

Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen
por: Hébert, Vivien, et al.
Publicado: (2021)

Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen
por: Hébert, Vivien, et al.
Publicado: (2019)

IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
por: Font, Guillaume, et al.
Publicado: (2022)

FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus
por: Maho-Vaillant, Maud, et al.
Publicado: (2022)

Dsg3 epitope-specific signalling in pemphigus
por: Schmitt, Thomas, et al.
Publicado: (2023)

CD11c(+) B Cells Are Mainly Memory Cells, Precursors of Antibody Secreting Cells in Healthy Donors
por: Golinski, Marie-Laure, et al.
Publicado: (2020)

Role of Dsg1- and Dsg3-Mediated Signaling in Pemphigus Autoantibody-Induced Loss of Keratinocyte Cohesion
por: Walter, Elias, et al.
Publicado: (2019)

Mucosal pemphigus vulgaris anti-Dsg3 IgG are pathogenic to the oral mucosa of humanized Dsg3 mice
por: Culton, Donna A., et al.
Publicado: (2015)

Dsg2 Upregulation as a Rescue Mechanism in Pemphigus
por: Sigmund, Anna M., et al.
Publicado: (2020)

Dsg1 and Dsg3 Composition of Desmosomes Across Human Epidermis and Alterations in Pemphigus Vulgaris Patient Skin
por: Schmitt, Thomas, et al.
Publicado: (2022)

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect
por: Chen, D.M., et al.
Publicado: (2019)

Targeted Immunotherapy with Rituximab Leads to a Transient Alteration of the IgG Autoantibody Profile in Pemphigus Vulgaris
por: Müller, Ralf, et al.
Publicado: (2010)

A SYSTEMATIC METANALYSIS ON DIAGNOSTIC VALUE OF DsG3 ELISA FOR PEMPHIGUS VULGARIS
por: Wiwanitkit, Viroj
Publicado: (2009)

Drugs responsible of DRESS syndrome regulate IL-10 and TNF-α secretion
por: Calbo, Sébastien, et al.
Publicado: (2014)

Superficial Dsg2 Expression Limits Epidermal Blister Formation Mediated by Pemphigus Foliaceus Antibodies and Exfoliative Toxins
por: Brennan, Donna, et al.
Publicado: (2010)

Rituximab in the Treatment of Pemphigus Vulgaris
por: Zakka, Labib R., et al.
Publicado: (2012)

Linear IgA bullous dermatosis treated with rituximab
por: Pinard, Camille, et al.
Publicado: (2019)

Rituximab therapy improves recalcitrant Pemphigus vulgaris
por: Noormohammadpour, Pedram, et al.
Publicado: (2015)

Rituximab in Pemphigus: Road Covered and Challenges Ahead
por: Vinay, Keshavamurthy, et al.
Publicado: (2018)

Cerebral toxoplasmosis after rituximab for pemphigus vulgaris
por: Lee, Erica B., et al.
Publicado: (2019)

Rituximab Therapy for Treatment of Pemphigus in Southeast Asians
por: Kanokrungsee, Silada, et al.
Publicado: (2021)

Negative Expression of DSG1 and DSG2, as Prognostic Biomarkers, Impacts on the Overall Survival in Patients with Extrahepatic Cholangiocarcinoma
por: Xu, Shu, et al.
Publicado: (2020)

Pemphigus: Current and Future Therapeutic Strategies
por: Didona, Dario, et al.
Publicado: (2019)

AZD-1222/rituximab: Pemphigus vulgaris and pemphigus vulgaris flare-up: 2 case reports
Publicado: (2022)

Off-label use of rituximab in dermatology: pemphigus treatment
por: Bomm, Lislaine, et al.
Publicado: (2013)

Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil
por: Biot, Stephanie Del Rio Navarrete, et al.
Publicado: (2014)

Rituximab therapy in pemphigus and other autoantibody-mediated diseases
por: Ran, Nina A., et al.
Publicado: (2017)

Follow-up Data of Rituximab as Adjuvant Therapy in Pemphigus
por: Khopkar, Uday S, et al.
Publicado: (2017)

Efficacy of rituximab in pediatric pemphigus: A literature review
por: Patel, Meera H., et al.
Publicado: (2021)

Rituximab: Aggressive course of pemphigus vulgaris: case report
Publicado: (2021)

Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris
por: BAUM, Sharon, et al.
Publicado: (2020)

Successful Treatment of Recalcitrant Pediatric Pemphigus Vulgaris With Rituximab
por: Santiago-Vázquez, Marely, et al.
Publicado: (2022)

Lack of association between chilblains outbreak and severe acute respiratory syndrome coronavirus 2: Histologic and serologic findings from a new immunoassay
por: Hébert, Vivien, et al.
Publicado: (2020)

Real world evidence: Patients with refractory pemphigus treated with Rituximab
por: Perifani, Vagiani, et al.
Publicado: (2021)

Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy
por: Benesh, Gabrielle, et al.
Publicado: (2021)

Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability
por: Ciolfi, Christian, et al.
Publicado: (2022)

Thrombotic Storm Induced by Rituximab in a Patient With Pemphigus Vulgaris
por: Karan, Abhinav, et al.
Publicado: (2023)

B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
por: Berkani, Nicolas, et al.
Publicado: (2019)

Author Correction: B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
por: Berkani, Nicolas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i4eqa5oojpdnn25r7fitogbm64